The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

Laurence BoothDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

Jane L. RobertsDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

Andrew PoklepovicDepartment of Medicine, Virginia Commonwealth University, Richmond, VA, USA

John KirkwoodUniversity of Pittsburgh Cancer Institute, Melanoma and Skin Cancer Program, Hillman Cancer Research Pavilion Laboratory L1.32c, Pittsburgh, PA, USA

Cindy SanderUniversity of Pittsburgh Cancer Institute, Melanoma and Skin Cancer Program, Hillman Cancer Research Pavilion Laboratory L1.32c, Pittsburgh, PA, USA

http://orcid.org/0000-0002-4136-1342

Francesca Avogadri-ConnorsPuma Biotechnology Inc. 1880 Wilshire Blvd, Los Angeles, CA, USA

Richard E. Cutler JrPuma Biotechnology Inc. 1880 Wilshire Blvd, Los Angeles, CA, USA

Alshad S. LalaniPuma Biotechnology Inc. 1880 Wilshire Blvd, Los Angeles, CA, USA

Paul DentDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USACorrespondence[email protected]

show all

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

supp_mat_1394556_KCBT.pdf

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

supp_mat_1394556_KCBT.pdf

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date